This information is intended for healthcare professionals based in Ireland.
If you are not a healthcare professional in Ireland, click here
This information is intended for healthcare professionals based in Ireland.
If you are not a healthcare professional in Ireland, click here
Choose ELIQUIS® to protect your patients with DVT / PE
ELIQUIS (apixaban) – an oral, direct factor Xa inhibitor - is indicated for:
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.1
- Prevention of Venous Thromboembolic Event (VTE) in adult patients who have undergone elective hip or knee replacement surgery.1
Robust clinical evidence for ELIQUIS in patients with DVT / PE
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1
Footnotes:
- CRNM = Clinically Relevant Non-Major DVT = Deep Vein Thrombosis PE = Pulmonary Embolism
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics.
- Agnelli G et al. N Engl J Med 2013; 369: 799–808.
- Agnelli G et al. N Engl J Med 2013; 368: 699–708.
- Weycker D et al. Thromb Haemost 2018; 118: 1951–1961.
Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie
Adverse reactions should also be reported to Bristol Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com